ESP Blocks for Posterior Spinal Fusion
ConditionPostoperative Pain
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-75
SponsorDuke University
About this trial
This prospective randomized double-blind study evaluates the efficacy of erector spinae plane (ESP) blocks on postoperative pain in patients undergoing cervical or lumbar posterior spinal fusion. Patients will receive either 0.5% bupivacaine plus liposomal bupivacaine or 0.5% plain bupivacaine. Outcomes include opioid consumption over 72 hours, pain scores, length of stay, and time to ambulation.
Eligibility criteria
Qualifiers
English speaking
Age 18-75
ASA physical status 1-3
Undergoing elective cervical or lumbar posterior spinal fusion (≤3 levels)
Disqualifiers
Age <18 or >75
ASA IV or V
Non-English speaking
BMI >40
Trial design
Treatments tested in this trial
- ESP Block with Bupivacaine
- ESP Block with Bupivacaine + Liposomal Bupivacaine
Treatment groups
75 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov